Active Clinical Trials
Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.
- Sort by Sort ascending
- Study title
- Condition
- Phase
- Location
- NCT ID
| Study title | Condition | Phase | Location | NCT ID |
|---|---|---|---|---|
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE) |
Sickle Cell Disease | Phase3 | Brazil Colombia Kenya Uganda United States View all |
NCT06439082 |
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA) |
Spinal Muscular Atrophy (SMA) | Greece Ireland Israel Poland Portugal Romania Russia South Korea Taiwan United States View all |
NCT04174157 | |
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma |
Asthma | Phase3 | Argentina Brazil Bulgaria Colombia Greece Guatemala Hungary Italy Mexico Panama Portugal Romania South Africa Spain Vietnam View all |
NCT05562466 |
Home Reported Outcomes in PNH |
Paroxysmal Nocturnal Hemoglobinuria | United States | NCT06411626 | |
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis |
Diffuse Cutaneous Systemic Sclerosis | Phase2 | Argentina Austria Belgium Brazil China France Germany Greece Hungary India Italy Japan Malaysia Mexico Portugal South Korea Spain Taiwan Thailand Turkey (Türkiye) United States View all |
NCT06470048 |
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma |
Asthma | Phase2 | Bulgaria Colombia Guatemala Hungary Poland South Africa Spain United Kingdom View all |
NCT05222529 |
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis |
Scleroderma, Diffuse | Phase2 | Argentina Australia Austria Belgium Brazil Czechia Denmark France Germany Hungary Israel Italy Japan Mexico Netherlands Singapore South Korea Spain Switzerland Taiwan United Kingdom United States View all |
NCT06655896 |
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V |
Lupus Nephritis | Phase2 | China France Germany Hungary India Malaysia Philippines Portugal Puerto Rico Singapore Spain Turkey (Türkiye) United States View all |
NCT05268289 |
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors |
Solid Tumor | Phase1, Phase2 | Australia Canada France Italy Spain United States View all |
NCT04939610 |
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). |
Systemic Lupus Erythematosus | Phase3 | Argentina Australia Brazil Bulgaria Canada Chile China Colombia Czechia France Germany Guatemala Hungary India Israel Italy Japan Malaysia Mexico Poland Portugal Romania Slovakia South Africa South Korea Spain Taiwan Thailand United States View all |
NCT06133972 |